Essential medicines

    Overview

    Medicines are a fundamental part of health care and a well-controlled functional pharmaceutical sector is a pre-requisite for universal health coverage, but countries in South-East Asia face numerous obstacles to medicines management.

    An estimated 40% of health budgets in low and middle income countries are spent on medicines, with much of the cost borne out-of-pocket by patients. Widespread health system inefficiencies mean that up to a quarter of spending on medicines is wasted due to poor procurement and irrational use, substandard and expired medicines. There has been under-investment in supply chain systems and regulatory systems as well as inadequate monitoring of medicines management.

    WHO supports Member States by

    • Supporting them to formulate evidence-based policies to ensure affordable access to quality safe and effective medicines and medical products and ensure good practices for implementation of these national policies;

    • Support countries to address priority and emerging health needs, such as anti-microbial resistance or non-communicable diseases by providing specific technical support to develop national \medicines policies, essential medicines lists, formularies and clinical guidelines to improve rational use and to build national capacity for effective regulatory systems and drug supply chain management;

    • Work with countries to assess and monitor progress by collecting data on medicines availability, use, assessing regulatory systems and medicines policy implementation as part of progress toward Universal Health Coverage.

    News

    All →

    Latest publications

    All →
    Maximum Retail Pricing Policy in the WHO South-East Asia Region

    Access to essential medicines is a pressing issue in the WHO South-East Asia Region, where inadequate public health funding forces millions to bear high...

    Monitoring progress on universal health coverage and the health-related Sustainable Development Goals in the South-East Asia Region - 2024 update

    The ninth annual report on Monitoring progress on universal health coverage and the health-related Sustainable Development Goals in the South-East Asia...

    Consumption and Rational use of Antimicrobials in South-East Asia Region, 2024

    The monitoring of antimicrobial consumption (AMC) is an indispensable component of national efforts aimed at mitigating the growing threat of antimicrobial...

    Access Medical Products in the South-East Asia Region 2023

    Improving access to essential medicines is important, with far-reaching implications for individuals and societies at large. At its core, this endeavour...

    Meeting reports

    All →

    The 7th Asia-Pacific Network on Access to Medicines under Universal Health Coverage (UHC) workshop took place in Delhi, India, from June 13th to 14th,...

    Workshop of the public procurement agencies in the WHO South-East Asia Region on improving access to medicines report page

    The inaugural workshop for public procurement agencies, held from July 11th to 13th, 2023, successfully brought together public procurement agencies from...

    Country policies, profiles and information

    Countries / Links to the Drug Regulatory Authorities

    National medicines policies

    Pharmaceutical sector country

    Country situational analyses

    Essential Medicines Lists

     
    A national drug policy sets a government’s long-term goals for the pharmaceutical sector and provides a framework for action by both the public and the private sectors
    A comprehensive assessment of the pharmaceutical sector identifies gaps, informs the design of effective interventions and enables evaluation of the impact of interventions over time.
    These are generated using a workbook tool to analyze medicines in health care delivery. They involve data collection on medicines use and availability, policy implementation and regulations enforcement.
    Essential medicines are those that satisfy the priority health care needs of the population. Which medicines are on the list depends on disease prevalence, current best evidence and cost-effectiveness.
    Bangladesh 2005n/a20152008
    Bhutan 2007n/a20152016
    DPR Korean/an/a20122012
    Indian/a20112013- KarnatakaRajasthan2015
    Indonesia 2006201120112011
    Maldives2007201120142009
    Myanmarn/an/a20142010
    Nepal2007201120142011
    Sri Lanka2006201120152013_14
    Thailandn/an/a20152012
    Timor-Leste2010n/a20122010